Betamethasone Valerate in Foam Vehicle is Effective with Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the Treatment of Scalp Psoriasis

Abstract

BMV foam is effective for scalp psoriasis with both once-a-day and twice-a-day use. This feature of the BMV foam is encouraging for expected improvement in clinical use.

A novel foam vehicle for delivery of topical corticosteroids

“…In studies of CP and BMV foam, the most common adverse events were burning, itching, and dryness at the site of application, which occurred, depending on the study, at rates similar to the active comparator (ie, corticosteroid in lotion) or to placebo, and possibly were the result of the alcohol normally present in foam and lotion formulations. [24][25][26][27][28][29][30][31] Furthermore, in at least one study, reports of application site reactions diminished in active treatment groups versus placebo groups; the investigators speculated that this may have been the result of the healing of damaged skin. 28 Finally, the new foam may offer some advantages in ethnic groups in which unique traits in skin or hair have been identified.…”

Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation

“…As in patients treated for severe psoriasis (19,20), this chronic psoriasiform skin disease of the CD18 hypo PL/J mouse model can be suppressed by corticosteroids (dexamethasone), suggesting the involvement of an inflammatory process. T cells are important in the generation of the inflammatory skin disease in this CD18 hypo PL/J model (21).…”

Statistical Significance and Clinical Relevance

“…7 The trial included 79 patients randomized to treatment either once daily or twice daily for 4 weeks. Patients were evaluated at 0 and 4 weeks by a blinded physician grader who graded the scalp for signs and symptoms of psoriasis.…”